1
|
Singh K, Tripathi RP. Carbohydrate derivatives fight against malaria parasite as anti-plasmodial agents. Carbohydr Res 2023; 531:108887. [PMID: 37399772 DOI: 10.1016/j.carres.2023.108887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 06/04/2023] [Accepted: 06/21/2023] [Indexed: 07/05/2023]
Abstract
Malaria, a prevalent fatal disease around the world is caused by Plasmodium sp. and is transmitted by the bite of female Anopheles mosquito. It is leading cause of death in this century among most infectious diseases. Drug resistance was reported for almost every front-line drug against the deadliest species of the malarial parasite, i.e., Plasmodium falciparum. In the evolutionary arms race between parasite and existing arsenals of drugs new molecules having novel mechanism of action is urgently needed to overcome the drug resistance. In this review, we have discussed the importance of carbohydrate derivatives of different class of compounds as possible antimalarials with emphasis on mode of action, rational design, and SAR with improved efficacy. Carbohydrate-protein interactions are increasingly important for medicinal chemists and chemical biologists to understand the pathogenicity of the parasite. Less is known about the carbohydrate-protein interactions and pathogenicity in the Plasmodium parasite. With the increased knowledge on protein-sugar interaction and glycomics of Plasmodium parasites, carbohydrate derivatives can surpass the existing biochemical pathways responsible for drug resistance. The new candidates with novel mode of action will prove to be a potent antimalarial drug candidate without any parasitic resistance.
Collapse
Affiliation(s)
- Kartikey Singh
- Department of Chemistry, Wayne State University, Detroit, MI, 48202, United States.
| | - Rama Pati Tripathi
- CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, Uttar Pradesh, India.
| |
Collapse
|
2
|
Kurian J, Kumari V, Chaluvalappil SV, Anas M, Manhas A, Kalluruttimmal R, Kumar N, Manheri MK. Adenine Modification at C7 as a Viable Strategy to Potentiate the Antimalarial Activity of Quinolones. ChemMedChem 2021; 17:e202100472. [PMID: 34717044 DOI: 10.1002/cmdc.202100472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 10/15/2021] [Indexed: 11/08/2022]
Abstract
Although many quinolones have shown promise as potent antimalarials, their clinical development has been slow due to poor performance in vivo. Insights into structural modifications that can improve their therapeutic potential will be very valuable in this vibrant area of research. Our studies involving a library of quinolones which vary in substitution pattern at N1, C3, C6 and C7 positions have shown that the presence of adenine moiety at C7 can bring a noticeable improvement in activity compared to other heterocyclic groups at this location. The most potent compound emerged from this study showed IC50 values of 0.38 μM and 0.75 μM against chloroquine-sensitive and -resistant (W2) strains, respectively. Docking analysis in the Qo site of cytochrome bc1 complex revealed the contribution of a key H-bonding interaction from the adenine unit in target binding. This corroborates with compound-induced loss of mitochondrial functions. These findings not only open avenues for further exploration of antimalarial potential of adenine-modified quinolones, but also suggests broader opportunities during lead-optimization against other antimalarial targets.
Collapse
Affiliation(s)
- Jais Kurian
- Department of Chemistry, Indian Institute of Technology Madras, Chennai 600036, Tamil Nadu, India
| | - Varsha Kumari
- Department of Molecular Microbiology and Immunology, CSIR-Central Drug Research Institute, Sector 10, Jankipuram extension, Sitapur road, Lucknow, 226031, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - Saheer V Chaluvalappil
- Department of Chemistry, Krishna Menon Memorial Government Women's College, Kannur 670004, Kerala, India
| | - Mohammad Anas
- Department of Molecular Microbiology and Immunology, CSIR-Central Drug Research Institute, Sector 10, Jankipuram extension, Sitapur road, Lucknow, 226031, India
| | - Ashan Manhas
- Department of Molecular Microbiology and Immunology, CSIR-Central Drug Research Institute, Sector 10, Jankipuram extension, Sitapur road, Lucknow, 226031, India
| | - Ramshad Kalluruttimmal
- Department of Chemistry, Indian Institute of Technology Madras, Chennai 600036, Tamil Nadu, India
| | - Niti Kumar
- Department of Molecular Microbiology and Immunology, CSIR-Central Drug Research Institute, Sector 10, Jankipuram extension, Sitapur road, Lucknow, 226031, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - Muraleedharan K Manheri
- Department of Chemistry, Indian Institute of Technology Madras, Chennai 600036, Tamil Nadu, India
| |
Collapse
|
3
|
Martinez-Peinado N, Lorente-Macías Á, García-Salguero A, Cortes-Serra N, Fenollar-Collado Á, Ros-Lucas A, Gascon J, Pinazo MJ, Molina IJ, Unciti-Broceta A, Díaz-Mochón JJ, Pineda de las Infantas y Villatoro MJ, Izquierdo L, Alonso-Padilla J. Novel Purine Chemotypes with Activity against Plasmodium falciparum and Trypanosoma cruzi. Pharmaceuticals (Basel) 2021; 14:ph14070638. [PMID: 34358064 PMCID: PMC8308784 DOI: 10.3390/ph14070638] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 06/24/2021] [Accepted: 06/26/2021] [Indexed: 11/16/2022] Open
Abstract
Malaria and Chagas disease, caused by Plasmodium spp. and Trypanosoma cruzi parasites, remain important global health problems. Available treatments for those diseases present several limitations, such as lack of efficacy, toxic side effects, and drug resistance. Thus, new drugs are urgently needed. The discovery of new drugs may be benefited by considering the significant biological differences between hosts and parasites. One of the most striking differences is found in the purine metabolism, because most of the parasites are incapable of de novo purine biosynthesis. Herein, we have analyzed the in vitro anti-P. falciparum and anti-T. cruzi activity of a collection of 81 purine derivatives and pyrimidine analogs. We firstly used a primary screening at three fixed concentrations (100, 10, and 1 µM) and progressed those compounds that kept the growth of the parasites < 30% at 100 µM to dose–response assays. Then, we performed two different cytotoxicity assays on Vero cells and human HepG2 cells. Finally, compounds specifically active against T. cruzi were tested against intracellular amastigote forms. Purines 33 (IC50 = 19.19 µM) and 76 (IC50 = 18.27 µM) were the most potent against P. falciparum. On the other hand, 6D (IC50 = 3.78 µM) and 34 (IC50 = 4.24 µM) were identified as hit purines against T. cruzi amastigotes. Moreover, an in silico docking study revealed that P. falciparum and T. cruzi hypoxanthine guanine phosphoribosyltransferase enzymes could be the potential targets of those compounds. Our study identified two novel, purine-based chemotypes that could be further optimized to generate potent and diversified anti-parasitic drugs against both parasites.
Collapse
Affiliation(s)
- Nieves Martinez-Peinado
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
| | - Álvaro Lorente-Macías
- Department of Medicinal & Organic Chemistry and Excellence Research Unit of “Chemistry Applied to Biomedicine and the Environment”, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071 Granada, Spain; (Á.L.-M.); (J.J.D.-M.)
- Institute of Biopathology and Regenerative Medicine, Centre for Biomedical Research, University of Granada, Avda. del Conocimiento s/n, 18100 Granada, Spain;
- Cancer Research UK Edinburgh Centre, Institute of Genetics & Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK;
| | - Alejandro García-Salguero
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
| | - Nuria Cortes-Serra
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
| | - Ángel Fenollar-Collado
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
| | - Albert Ros-Lucas
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
| | - Joaquim Gascon
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
| | - Maria-Jesus Pinazo
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
| | - Ignacio J. Molina
- Institute of Biopathology and Regenerative Medicine, Centre for Biomedical Research, University of Granada, Avda. del Conocimiento s/n, 18100 Granada, Spain;
| | - Asier Unciti-Broceta
- Cancer Research UK Edinburgh Centre, Institute of Genetics & Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK;
| | - Juan J. Díaz-Mochón
- Department of Medicinal & Organic Chemistry and Excellence Research Unit of “Chemistry Applied to Biomedicine and the Environment”, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071 Granada, Spain; (Á.L.-M.); (J.J.D.-M.)
| | - María J. Pineda de las Infantas y Villatoro
- Department of Medicinal & Organic Chemistry and Excellence Research Unit of “Chemistry Applied to Biomedicine and the Environment”, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071 Granada, Spain; (Á.L.-M.); (J.J.D.-M.)
- Correspondence: (M.J.P.d.l.I.y.V.); (L.I.); (J.A.-P.); Tel.: +34-958249360 (M.J.P.d.l.I.y.V.); +34-932275400 (ext. 4569) (L.I.); +34-932275400 (ext. 4569) (J.A.-P.)
| | - Luis Izquierdo
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
- Correspondence: (M.J.P.d.l.I.y.V.); (L.I.); (J.A.-P.); Tel.: +34-958249360 (M.J.P.d.l.I.y.V.); +34-932275400 (ext. 4569) (L.I.); +34-932275400 (ext. 4569) (J.A.-P.)
| | - Julio Alonso-Padilla
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
- Correspondence: (M.J.P.d.l.I.y.V.); (L.I.); (J.A.-P.); Tel.: +34-958249360 (M.J.P.d.l.I.y.V.); +34-932275400 (ext. 4569) (L.I.); +34-932275400 (ext. 4569) (J.A.-P.)
| |
Collapse
|
4
|
Thakur RK, Joshi P, Upadhyaya K, Singh K, Sharma G, Shukla SK, Tripathi R, Tripathi RP. Synthesis of isatin based N1-alkylated 3-β-C-glycoconjugated-oxopropylidene oxindoles as potent antiplasmodial agents. Eur J Med Chem 2019; 162:448-454. [DOI: 10.1016/j.ejmech.2018.11.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2018] [Revised: 11/03/2018] [Accepted: 11/05/2018] [Indexed: 02/08/2023]
|